1) Jimenez C, et al : Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 15 : 356-371, 2013
2) John H, et al : Pheochromocytomas : can malignant potential be predicted? Urology 53 : 679-683, 1999
3) Niemeijer ND, et al : Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma : systematic review and meta-analysis. Clin Endocrinol (Oxf) 81 : 642-651, 2014
4) Sisson J, et al : Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 96 : 209-217, 1983
5) van Hulsteijn LT, et al :(131)I-MIBG therapy for malignant paraganglioma and pheochromocytoma : systematic review and meta-analysis. Clin Endocrinol (Oxf) 80 : 487-501, 2014
6) Loh KC, et al : The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG) : a comprehensive review of 116 reported patients. J Endocrinol Invest 20 : 648-658, 1997
7) Wiseman GA, et al : Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma : results from a prospective multicenter trial. J Nucl Med 50 : 1448-1454, 2009
I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma : results of a meta-analysis. J Clin Endocrinol Metab 95 : 2596-2606, 2010
9) Shapiro B, et al : Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG : clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 15 : 170-177, 1987